Automatic Drug Injector “Rejumate Injector” approved by CE-MDD
pain and works in synergy with Rejuran. Laid the foundation to enter the
PharmaReseach Co. Ltd. announced on the 26th
that the automatic drug injector “Rejumate Injector” obtained the medical
device approval of the EU, CE-MDD.
CE-MDD(Medical Device Directive) is a CE mark
according to the EU’s Medical Device Directive and it’s a requested
certification for entering into the European market. It is issued only for the
products which conform to their strict standards of quality, performance,
safety, durability, among others.
With this certification, Rejumate Injector
has been globally recognized for its quality and safety, laying the foundation
for expanding the business to the European market.
The PharmaReseach representative stated that
“with the CE-MDD certification, Rejumate Injector laid the foundation to enter
the global market” and “our company plans to keep researching and developing
medical devices that satisfy consumers’ needs, in order to contribute to the
growth of the national beauty industry and gain influence in global markets”.
Meanwhile, “Rejumate Injector” is a medical
device that administers drugs automatically into the skin using 9 pins of 34G
thin sterilized needles, and compared to the traditional syringe, it has the
advantage of reducing pain and injecting the exact targeted amount of drugs. Since
its launch in the second half of 2020, its market share has been increasing in
synergy with PharmaReseach’s emblematic product, Rejuran.